Semaglutide
640 RCTsFDA approved
| Produces clinically meaningful weight loss | supported |
| Improves glycaemic control in type 2 diabetes | supported |
| Free of side effects | overreach |
Goal matrix
Metabolic & fat loss
Every compound we track for this goal.
3 FDA approved2 Extensively studied1 Well researched2 Emerging5 Limited evidence
01
The matrix
Tirzepatide
210 RCTsFDA approved
| Greater average weight loss than semaglutide | supported |
| Requires no medical supervision | overreach |
Tesamorelin
38 RCTsFDA approved
| Reduces visceral fat in HIV-associated lipodystrophy | supported |
| Produces general fat loss in healthy adults | weak evidence |
| Improves cognition in ageing | weak evidence |
Survodutide
14 RCTsExtensively studied
| Produced double-digit mean body-weight reduction over 76 weeks in a phase 3 randomised trial | supported |
| Improves MASH histology without worsening fibrosis | partially true |
| The glucagon arm raises energy expenditure more than GLP-1-only agents do | weak evidence |
| An approved prescription obesity treatment | overreach |
Mazdutide
13 RCTsExtensively studied
| Approved by China's NMPA for chronic weight management in adults | supported |
| Produced roughly 15% mean body-weight reduction at the higher dose in a phase 3 trial | supported |
| Outperforms semaglutide for weight loss | weak evidence |
| FDA approved in the United States | overreach |
Retatrutide
18 RCTsWell researched
| Largest weight loss of any trialled agent to date | partially true |
| Approved and available | overreach |
Cagrilintide
19 RCTsEmerging
| Promotes satiety through the amylin pathway | supported |
| Adds weight loss when combined with semaglutide | partially true |
| Proven as a standalone weight-loss therapy | weak evidence |
MOTS-c
7 RCTsEmerging
| Improves exercise capacity | animal data only |
| Regulates metabolism via mitochondrial signalling | preclinical only |
| Reverses metabolic disease in humans | overreach |
Tesamorelin / Ipamorelin blend
—Limited evidence
| Mechanistically complementary GH stimulation | partially true |
| Covered by tesamorelin regulatory approval | overreach |
Triple Threat blend
—Limited evidence
| Boosts energy and metabolism | weak evidence |
| Each component is clinically proven | overreach |
5-Amino-1MQ
0 RCTsLimited evidence
| Is a peptide | overreach |
| Shrinks fat cells | animal data only |
| Produces fat loss in humans | weak evidence |
AOD-9604
0 RCTsLimited evidence
| Burns fat without growth-hormone side effects | weak evidence |
| Failed to beat placebo in human trials | supported |
SLU-PP-332
0 RCTsLimited evidence
| Activates ERR-alpha, ERR-beta and ERR-gamma in cell-based assays | preclinical only |
| Increases running endurance in mice | animal data only |
| Reduces fat mass and improves insulin sensitivity in obese mouse models | animal data only |
| Delivers the benefits of exercise in humans without exercising | overreach |
02